


## SIGLEC7 Antibody (F40103)


| Catalog No.   | Formulation                                | Size    |
|---------------|--|---------|
| F40103-0.4ML  | In 1X PBS, pH 7.4, with 0.09% sodium azide | 0.4 ml  |
| F40103-0.08ML | In 1X PBS, pH 7.4, with 0.09% sodium azide | 0.08 ml |

[Bulk quote request](#)

|                    |   |
|--------------------|---|
| Availability       | 1-3 business days   |
| Species Reactivity | Human   |
| Format             | Antigen affinity purified                                 |
| Clonality          | Polyclonal (rabbit origin)                                |
| Isotype            | Rabbit Ig   |
| Purity             | Antigen affinity  |
| UniProt            | Q9Y286  |
| Applications       | Western blot : 1:1000<br>IHC (Paraffin) : 1:50-1:100      |
| Limitations        | This SIGLEC7 antibody is available for research use only. |



Western blot analysis of SIGLEC7 antibody and NCI-H460 lysate.



IHC analysis of FFPE human breast carcinoma stained with the SIGLEC7 antibody

## Description

SIGLECs are cell surface proteins of the Ig superfamily. Most SIGLECs have 1 or more cytoplasmic immune receptor tyrosine-based inhibitory motifs, or ITIMs. A large subgroup of SIGLECs share high homology with SIGLEC3 (CD33) and are localized to 19q13.4. The cDNA for the SLG gene encodes 2 variants, SLG-long (SLGL) and SLG-short (SLGS). The 595-amino acid SLGL protein contains a signal peptide and 2 V-set N-terminal Ig-like domains. The 477-amino acid SLGS protein has a weak signal sequence and, like most SIGLEC3-like SIGLECs, has only 1 V-set N-terminal Ig-like domain. Both variants contain 2 C2-set N-terminal Ig-like domains, a transmembrane domain, and a cytoplasmic tail with a putative ITIM and a putative SLAM-like tyrosine-based motif. The conserved arginine residue thought to be essential for sialic acid binding in other SIGLECs is replaced by a glutamine in SLGS and by a cysteine in SLGL. RT-PCR analysis detected high expression of both variants in spleen and small intestine, and SLGS was highly expressed in adrenal gland and SLGL was highly expressed in bone marrow.

## Application Notes

Titration of the SIGLEC7 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

## Immunogen

A portion of amino acids 1-30 from the human protein was used as the immunogen for this SIGLEC7 antibody.

## Storage

Aliquot the SIGLEC7 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.